<DOC>
	<DOCNO>NCT00561379</DOCNO>
	<brief_summary>The aim protocol compare outcome patient DLBCL stage II bulky , III IV 1 3 adverse prognostic factor accord International prognostic index . Patients eligibility criterion give inform consent randomise CHOP-14- Rituximab x 8 course High dose chemotherapy rituximab include autologous stem cell support . The aim study compare Event free survival two arm gain insight prognostic significance several biological marker gather time diagnosis/randomisation ( i.e . Fcgamma R III A genotyping , DNA profile BCL é expression ) .</brief_summary>
	<brief_title>Diffuse Large B Cell Lymphoma Adult : Randomization Between High Dose Chemotherapy With Rituximab CHOP 14-Rituximab</brief_title>
	<detailed_description>Diffuse Large B Cell Lymphoma previously treat</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Age ≥ 18 et ≤ 60 male female Diffuse large B cell lymphoma accord WHO classification phénotype B CD 20 + Stage I et II tumor bulk &gt; 7 cm stage III et IV Ann Arbor . Non previously treat HIV négative Signed inform consent Age &lt; 18 and/or &gt; 60 an NHL DLBCL Lymphoblastic Lymphoma Burkitt 's Lymphoma Low grade Lymphoma transform Primary CNS Lymphomal Post transplantation Lymphoma CD20 negative Ann Arbor stage I II without tumor bulk &gt; 7 cm Previous treatment HIV positive Contreindication Rituximab use accord SmPC Contreindication high dose chemotherapy due organ failure relate lymphoma Cancer history cancer exception situ cancer cervix noninvasive skin epithelioma Patient able understand propose treatment Refusal sign inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Diffuse Large B Cell Lymphoma</keyword>
	<keyword>previously treat</keyword>
</DOC>